There has been several studies about ALDH1 cells which has the ability to form breast tumors. However, there is still controversy about these findings. However, as there are still controversies, verification of these findings are needed. Recently, the author evaluated the relationship between the prevalence of ALDH1 tumor cells and their prognostic value in breast cancer patients. The study analyzed the association of survival outcomes with molecular subtypes of breast cancer with ALDH1 status. The result of this study showed that ALDH1 expression was related with worse survival outcomes as well as higher incidence of triple negative breast cancer. Our findings suggest that ALDH1 + expression is related with poor prognostic features and contribute to aggressive natures.
Breast cancer is the most frequent women cancer in the whole wild world, and its therapeutic resistance is the biggest problem [1, 2] . One of the theories that could explain treatment failure is cancer stem cell (CSC) theory [3] . CSC is the tumor cell population that is capable of self-renewal and differentiation, giving rise to a heterogeneous tumor cell population and resistance to anticancer therapy [4] .
Several markers, such as CD44, CD24 and aldehyde dehydrogenase 1 (ALDH1), have been proposed as cancer stem cell markers [5] . Based on the cell surface markers, Al Hajj et al. [6] firstly separated carcinogenic cell population of breast cancer cells. It was found that CD44 + /CD24 -cells were able to form tumors, whereas the alternate phenotypes failed to form tumors in mice. Ginestier et al. [7] found that ALDH1 + tumor cells were capable of generating tumors in nude mice with low cell population. In addition, when ALDH1 positivity was combined with the marker set of CD44 + /CD24 -, those tumor cells could develop tumors with fewer cells than ALDH1 + alone in nude mice when transplanted orthotopically into fat pad.
While these CSCs have been associated with poor prognosis in some breast cancer patients, the relationship between CSCs and tumor recurrence remains unclear. Some studies reported that disease free survival (DFS) was poorer in CSC positive patients [2, 8, 9] . However, other reports documented that the presence of CSCs was not associated with clinical outcomes [10] [11] [12] .
Therefore, the present author investigated the importance of CSC phenotype in the survival outcomes of breast cancer cells [13] . The report analyzed the immunohistochemical expression of the breast CSC marker, ALDH1, in a sample of 70breast cancers with invasive ductal carcinoma. The study has used IHC expression of ALDH1 as breast CSC marker
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and evaluated its correlation with survival outcomes, such as DFS and overall survival (OS). The present author showed in this study that ALDH1 + tumors had a significant tendency toward shorter survival outcomes compared with ALDH1 -tumors. With this result, we could speculate that the breast cancer cells with ALDH1 expression may be related with poor survival outcomes (Fig. 1 ).
In addition, as well known, there are several factors known to be important for the survival outcomes, such as tumor size, nodal status, hormonal receptor, human epidermal growth factor receptor (HER)-2 protein, molecular subtypes and so on. The association between ALDH1 expression and these factors are also still controversial. One previous reported that ALDH1 expression has no association with prognostic factors [8] . However, other two studies reported that the expression of ALDH1 was related with worse prognostic features such as high histologic grade, HER-2 over expression and absence of estrogen receptor (ER) and progesterone receptor (PR) [7, 14] . In this study, we were able to demonstrate an association between ALDH1 expression and ER negativity (Table 1) .
Breast cancer could be classified into four molecular subtypes defined by tumor markers, such as ER, PR and HER-2 protein [15, 16] . It is well known that triple negative breast cancer (TNBC) is the most aggressive subtype with the poorest prognosis, largely due to the lacking of targeted therapy. In this study, the author found that the ALDH1 + tumors are significantly related with TNBCs. Therefore, this result emphasizes the enrichment of CSCs in the aggressive tumor subtype (Table 1) .
In this study, ALDH1 + tumors showed shorter DFS than ALDH1 -. However, after correcting the frequency of molecular subtype, there were no significant DFS differences between ALDH1 + and ALDH1 -patients regardless of whether TNBC occurred or not. Therefore, when the tumor expressed ALDH1, shorter DFS may result from the high incidence of TNBC rather than ALDH1 expression itself. In the analysis of OS, the expression of ALDH1 was also associated with shorter OS. After compensating the incidence of molecular subtype, there was no statistical difference of OS between ALDH1 + and ALDH1 -in TNBC. In patients with non-TNBC, however, ALDH1 + tumors showed shorter OS than ALDH1
-. This result may mean that when the ALDH1 was expressed, poor OS of total patients came from that of non-TNBC patients. Thus, ALDH1 can be a contributed factor to determine OS rather than molecular subtype ( Fig. 2 and Table 2 ).
In conclusion, the expression of ALDH1is associated with the poorer clinical outcomes which shows worse survival outcomes and higher incidence of TNBC. The significant correlation of this marker with molecular subtype and clinical outcomes may suggest that the presence of ALDH1 + cells is associated with poor prognostic features and contribute to aggressive natures.
